U.S. markets closed
  • S&P Futures

    3,911.00
    -5.25 (-0.13%)
     
  • Dow Futures

    31,433.00
    -54.00 (-0.17%)
     
  • Nasdaq Futures

    12,134.25
    -6.25 (-0.05%)
     
  • Russell 2000 Futures

    1,759.00
    -2.70 (-0.15%)
     
  • Crude Oil

    107.63
    +0.01 (+0.01%)
     
  • Gold

    1,836.80
    +6.50 (+0.36%)
     
  • Silver

    21.34
    +0.22 (+1.02%)
     
  • EUR/USD

    1.0567
    +0.0009 (+0.08%)
     
  • 10-Yr Bond

    3.1250
    +0.0570 (+1.86%)
     
  • Vix

    27.23
    -1.82 (-6.27%)
     
  • GBP/USD

    1.2283
    +0.0014 (+0.11%)
     
  • USD/JPY

    134.8330
    -0.3370 (-0.25%)
     
  • BTC-USD

    21,071.56
    -292.35 (-1.37%)
     
  • CMC Crypto 200

    459.95
    +6.05 (+1.33%)
     
  • FTSE 100

    7,208.81
    +188.36 (+2.68%)
     
  • Nikkei 225

    26,748.82
    +256.85 (+0.97%)
     

Ionis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 48% loss from investing in the stock a year ago

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Unfortunately the Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) share price slid 48% over twelve months. That contrasts poorly with the market return of 5.9%. Notably, shareholders had a tough run over the longer term, too, with a drop of 46% in the last three years.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

See our latest analysis for Ionis Pharmaceuticals

Given that Ionis Pharmaceuticals didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

In just one year Ionis Pharmaceuticals saw its revenue fall by 29%. That looks pretty grim, at a glance. Shareholders have seen the share price drop 48% in that time. That seems pretty reasonable given the lack of both profits and revenue growth. It's hard to escape the conclusion that buyers must envision either growth down the track, cost cutting, or both.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

Ionis Pharmaceuticals is well known by investors, and plenty of clever analysts have tried to predict the future profit levels. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.

A Different Perspective

Ionis Pharmaceuticals shareholders are down 48% for the year, but the market itself is up 5.9%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 5% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Ionis Pharmaceuticals better, we need to consider many other factors. Even so, be aware that Ionis Pharmaceuticals is showing 1 warning sign in our investment analysis , you should know about...

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.